BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...Inc., a BeyondSpring Inc. (NASDAQ:BYSI) subsidiary, hired Edward Dongheng Liu as CFO. Liu was BeyondSpring’s CFO.MaxCyte Inc....
...KGaA Johnson & Johnson Janssen Pharmaceuticals ​ Innovent Biologics Inc. eFFECTOR Therapeutics Inc. Nautilus Biotechnology Inc. Epirium Bio Inc. Medeor Therapeutics Inc. BeyondSpring Inc. MaxCyte Inc. Kedrion...
BioCentury | Oct 14, 2020
Management Tracks

Anderson joining Sofinnova Partners to bridge European biotechs to public markets

...$31 million investment in cell therapy company MaxCyte Inc. (LSE:MXCT) at 131p per share. On Wednesday, MaxCyte...
BioCentury | Sep 12, 2020
Management Tracks

New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more

...David Bennett as COO. Bennett was most recently VP at Syneos Health Inc. Cell therapy play MaxCyte Inc....
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...and CD20 targets. The ASCO abstracts include preliminary data from a mesothelin-targeted cell therapy from MaxCyte Inc....
BioCentury | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

...and Colasin was a director of Bloom Science Inc., which he co-founded. Cell therapy company MaxCyte Inc....
...advising partner at Advantary, which outsources C-suite services. BioCentury Staff Xencor Institut Gustave-Roussy Zelluna Immunotherapy A/S E-Scape Bio Inc. Boston Pharmaceuticals Inc. MaxCyte Inc. Syros...
BioCentury | Oct 7, 2019
Company News

Oct. 7 Company Quick Takes: Editas-MaxCyte, Goldfinch-Takeda, Prometheus-Takeda, DBV and Galderma

...Editas licenses MaxCyte tech to develop engineered cell medicines Editas Medicine Inc. (NASDAQ:EDIT) licensed non-exclusive clinical...
...NASDAQ:EDIT) licensed non-exclusive clinical and commercial rights to Flow Electroporation technology and ExPERT instruments from MaxCyte Inc....
...disease and β thalassemia. Editas will develop up to five therapies, including four immuno-oncology therapies. MaxCyte...
BioCentury | Dec 15, 2018
Product Development

O’Day’s expansive task at Gilead

...following the Kite deal that gave it Yescarta axicabtagene ciloleucel. For example, a deal with MaxCyte Inc....
...Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. MaxCyte Inc....
BioCentury | Dec 14, 2018
Company News

Veteran Roche cancer executive O'Day to lead Gilead

...last month, Kite gained access to non-viral cell engineering technology through a research deal with MaxCyte Inc....
BioCentury | Dec 10, 2018
Company News

Veteran Roche cancer executive O'Day to lead Gilead

...last month, Kite gained access to non-viral cell engineering technology through a research deal with MaxCyte Inc....
BioCentury | Nov 16, 2018
Company News

MaxCyte partners with Kite, CRISPR in nonviral gene editing deals

...use its Flow Electroporation technology to engineer cells. Kite gains a non-exclusive license to use MaxCyte's...
...MaxCyte will receive licensing fees and is eligible for milestone and royalty payments. CRISPR and MaxCyte...
...for hemoglobin-related diseases and severe combined immunodeficiency (SCID) (see "MaxCyte, Casebia, CRISPR Therapeutics Deal" ). MaxCyte Inc....
Items per page:
1 - 10 of 53
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...Inc., a BeyondSpring Inc. (NASDAQ:BYSI) subsidiary, hired Edward Dongheng Liu as CFO. Liu was BeyondSpring’s CFO.MaxCyte Inc....
...KGaA Johnson & Johnson Janssen Pharmaceuticals ​ Innovent Biologics Inc. eFFECTOR Therapeutics Inc. Nautilus Biotechnology Inc. Epirium Bio Inc. Medeor Therapeutics Inc. BeyondSpring Inc. MaxCyte Inc. Kedrion...
BioCentury | Oct 14, 2020
Management Tracks

Anderson joining Sofinnova Partners to bridge European biotechs to public markets

...$31 million investment in cell therapy company MaxCyte Inc. (LSE:MXCT) at 131p per share. On Wednesday, MaxCyte...
BioCentury | Sep 12, 2020
Management Tracks

New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more

...David Bennett as COO. Bennett was most recently VP at Syneos Health Inc. Cell therapy play MaxCyte Inc....
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...and CD20 targets. The ASCO abstracts include preliminary data from a mesothelin-targeted cell therapy from MaxCyte Inc....
BioCentury | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

...and Colasin was a director of Bloom Science Inc., which he co-founded. Cell therapy company MaxCyte Inc....
...advising partner at Advantary, which outsources C-suite services. BioCentury Staff Xencor Institut Gustave-Roussy Zelluna Immunotherapy A/S E-Scape Bio Inc. Boston Pharmaceuticals Inc. MaxCyte Inc. Syros...
BioCentury | Oct 7, 2019
Company News

Oct. 7 Company Quick Takes: Editas-MaxCyte, Goldfinch-Takeda, Prometheus-Takeda, DBV and Galderma

...Editas licenses MaxCyte tech to develop engineered cell medicines Editas Medicine Inc. (NASDAQ:EDIT) licensed non-exclusive clinical...
...NASDAQ:EDIT) licensed non-exclusive clinical and commercial rights to Flow Electroporation technology and ExPERT instruments from MaxCyte Inc....
...disease and β thalassemia. Editas will develop up to five therapies, including four immuno-oncology therapies. MaxCyte...
BioCentury | Dec 15, 2018
Product Development

O’Day’s expansive task at Gilead

...following the Kite deal that gave it Yescarta axicabtagene ciloleucel. For example, a deal with MaxCyte Inc....
...Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. MaxCyte Inc....
BioCentury | Dec 14, 2018
Company News

Veteran Roche cancer executive O'Day to lead Gilead

...last month, Kite gained access to non-viral cell engineering technology through a research deal with MaxCyte Inc....
BioCentury | Dec 10, 2018
Company News

Veteran Roche cancer executive O'Day to lead Gilead

...last month, Kite gained access to non-viral cell engineering technology through a research deal with MaxCyte Inc....
BioCentury | Nov 16, 2018
Company News

MaxCyte partners with Kite, CRISPR in nonviral gene editing deals

...use its Flow Electroporation technology to engineer cells. Kite gains a non-exclusive license to use MaxCyte's...
...MaxCyte will receive licensing fees and is eligible for milestone and royalty payments. CRISPR and MaxCyte...
...for hemoglobin-related diseases and severe combined immunodeficiency (SCID) (see "MaxCyte, Casebia, CRISPR Therapeutics Deal" ). MaxCyte Inc....
Items per page:
1 - 10 of 53